147 related articles for article (PubMed ID: 17072654)
1. Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.
Lauria A; Ippolito M; Almerico AM
J Mol Model; 2007 Mar; 13(3):393-400. PubMed ID: 17072654
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
3. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
[TBL] [Abstract][Full Text] [Related]
4. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
[TBL] [Abstract][Full Text] [Related]
5. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives.
Laco GS
PLoS One; 2011; 6(8):e24314. PubMed ID: 21912628
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase I inhibitors: camptothecins and beyond.
Pommier Y
Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships.
Marco E; Laine W; Tardy C; Lansiaux A; Iwao M; Ishibashi F; Bailly C; Gago F
J Med Chem; 2005 Jun; 48(11):3796-807. PubMed ID: 15916431
[TBL] [Abstract][Full Text] [Related]
9. Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies.
Laco GS; Du W; Kohlhagen G; Sayer JM; Jerina DM; Burke TG; Curran DP; Pommier Y
Bioorg Med Chem; 2004 Oct; 12(19):5225-35. PubMed ID: 15351405
[TBL] [Abstract][Full Text] [Related]
10. A theoretical study of some new analogues of the anti-cancer drug camptothecin.
Jena NR; Mishra PC
J Mol Model; 2007 Jan; 13(1):267-74. PubMed ID: 17024403
[TBL] [Abstract][Full Text] [Related]
11. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
12. Structure and properties of camptothecin derivatives, their protonated forms, and model interaction with the topoisomerase I-DNA complex.
Ivanova B; Spiteller M
Biopolymers; 2012 Feb; 97(2):134-44. PubMed ID: 21898362
[TBL] [Abstract][Full Text] [Related]
13. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.
Xiao X; Cushman M
J Am Chem Soc; 2005 Jul; 127(28):9960-1. PubMed ID: 16011334
[TBL] [Abstract][Full Text] [Related]
14. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.
Cinelli MA; Morrell AE; Dexheimer TS; Agama K; Agrawal S; Pommier Y; Cushman M
Bioorg Med Chem; 2010 Aug; 18(15):5535-52. PubMed ID: 20630766
[TBL] [Abstract][Full Text] [Related]
15. Diversity of DNA topoisomerases I and inhibitors.
Pommier Y
Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I poisons and suppressors as anticancer drugs.
Bailly C
Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356
[TBL] [Abstract][Full Text] [Related]
17. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.
Fan Y; Shi LM; Kohn KW; Pommier Y; Weinstein JN
J Med Chem; 2001 Sep; 44(20):3254-63. PubMed ID: 11563924
[TBL] [Abstract][Full Text] [Related]
18. Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin.
Arimondo PB; Bailly C; Boutorine A; Sun JS; Garestier T; Hélène C
C R Acad Sci III; 1999 Sep; 322(9):785-90. PubMed ID: 10547719
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
